Vir Biotechnology Inc. (NASDAQ: VIR) reported Q4 EPS of $3.92, $0.88 better than the analyst estimate of $3.04. Revenue for the quarter came in at $812.7 million versus the consensus estimate of $622.9 million.

As of December 31, 2021, excluding restricted cash, the Company had approximately $909.5 million in cash, cash equivalents, and investments. Excluding restricted cash and its equity investment in Brii Biosciences, the Company had approximately $766.4 million in cash, cash equivalents and investments.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.